CRSP vs. EDIT

Last updated Apr 2, 2026

Compare and contrast key facts about CRISPR Therapeutics AG (CRSP) and Editas Medicine, Inc. (EDIT).

Performance

CRSP vs. EDIT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in CRISPR Therapeutics AG (CRSP) and Editas Medicine, Inc. (EDIT). The values are adjusted to include any dividend payments, if applicable.

CRSP vs. EDIT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CRSP CRISPR Therapeutics AG	-6.92%	33.23%	-37.12%	54.00%	-46.36%	-50.51%	151.39%	113.18%	21.68%	15.89%
EDIT Editas Medicine, Inc.	27.32%	61.42%	-87.46%	14.21%	-66.59%	-62.13%	136.78%	30.15%	-25.97%	89.34%

Fundamentals

EPS CRSP : -$5.47 EDIT : -$1.82
PS Ratio CRSP : 118.44 EDIT : 5.65
Total Revenue (TTM) CRSP : $36.75M EDIT : $40.52M
Gross Profit (TTM) CRSP : -$130.60M EDIT : $39.72M
EBITDA (TTM) CRSP : -$529.50M EDIT : $0.00

Returns By Period

In the year-to-date period, CRSP achieves a -6.92% return, which is significantly lower than EDIT's 27.32% return.

CRSP

• 1D: 2.61%
• 1M: -19.68%
• YTD: -6.92%
• 6M: -26.22%
• 1Y: 47.28%
• 3Y*: 2.57%
• 5Y*: -16.38%
• 10Y*: —

EDIT

• 1D: 5.67%
• 1M: 21.40%
• YTD: 27.32%
• 6M: -26.48%
• 1Y: 130.97%
• 3Y*: -28.86%
• 5Y*: -42.85%
• 10Y*: -23.27%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CRSP vs. EDIT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRSP

CRSP Risk / Return Rank: 64
CRSP Sharpe Ratio Rank: 66
CRSP Sortino Ratio Rank: 67
CRSP Omega Ratio Rank: 62
CRSP Calmar Ratio Rank: 63
CRSP Martin Ratio Rank: 60

EDIT

EDIT Risk / Return Rank: 77
EDIT Sharpe Ratio Rank: 81
EDIT Sortino Ratio Rank: 83
EDIT Omega Ratio Rank: 76
EDIT Calmar Ratio Rank: 77
EDIT Martin Ratio Rank: 72

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRSP vs. EDIT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and Editas Medicine, Inc. (EDIT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CRSP	EDIT	Difference
Sharpe ratio Return per unit of total volatility	0.75	1.34	-0.60
Sortino ratio Return per unit of downside risk	1.50	2.30	-0.81
Omega ratio Gain probability vs. loss probability	1.17	1.26	-0.09
Calmar ratio Return relative to maximum drawdown	1.03	2.09	-1.06
Martin ratio Return relative to average drawdown	2.03	3.96	-1.92
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CRSP vs. EDIT - Sharpe Ratio Comparison

The current CRSP Sharpe Ratio is 0.75, which is lower than the EDIT Sharpe Ratio of 1.34. The chart below compares the historical Sharpe Ratios of CRSP and EDIT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CRSP	EDIT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.75	1.34	-0.60
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.27	-0.46	+0.19
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.28	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.22	-0.21	+0.42

Correlation

The correlation between CRSP and EDIT is 0.66, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

CRSP vs. EDIT - Dividend Comparison

Neither CRSP nor EDIT has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CRSP vs. EDIT - Drawdown Comparison

The maximum CRSP drawdown since its inception was -85.11%, smaller than the maximum EDIT drawdown of -98.92%. Use the drawdown chart below to compare losses from any high point for CRSP and EDIT.

Drawdown Indicators

	CRSP	EDIT	Difference
Max Drawdown Largest peak-to-trough decline	-85.11%	-98.92%	+13.81%
Max Drawdown (1Y) Largest decline over 1 year	-42.25%	-59.88%	+17.63%
Max Drawdown (5Y) Largest decline over 5 years	-80.68%	-98.66%	+17.98%
Max Drawdown (10Y) Largest decline over 10 years	—	-98.92%	—
Current Drawdown Current decline from peak	-76.76%	-97.12%	+20.36%
Average Drawdown Average peak-to-trough decline	-48.71%	-61.99%	+13.28%
Ulcer Index Depth and duration of drawdowns from previous peaks	21.35%	31.57%	-10.22%

Volatility

CRSP vs. EDIT - Volatility Comparison

The current volatility for CRISPR Therapeutics AG (CRSP) is 18.14%, while Editas Medicine, Inc. (EDIT) has a volatility of 31.43%. This indicates that CRSP experiences smaller price fluctuations and is considered to be less risky than EDIT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CRSP	EDIT	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.14%	31.43%	-13.29%
Volatility (6M) Calculated over the trailing 6-month period	44.91%	60.52%	-15.61%
Volatility (1Y) Calculated over the trailing 1-year period	63.81%	98.25%	-34.44%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	60.36%	93.22%	-32.86%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	64.42%	83.41%	-18.99%

Financials